Home » Products » Anticancer Drugs » Canmab Trastuzumab 440 mg Injection

Canmab Trastuzumab 440 mg Injection

Canmab Trastuzumab 440 mg Injection
Canmab Trastuzumab 440 mg Injection
Send Inquiry
Product Code : 157
Price And Quantity
  • Minimum Order Quantity
  • 10
  • Unit of Measure
  • Box/Boxes
  • Price
  • 59981 INR
Product Specifications
  • Drug Type
  • Injection
  • Physical Form
  • Liquid
  • Function
  • Cancer Treatment
  • Dosage
  • 440 mg
  • Suitable For
  • Suitable For All, Aged Person, Adults, Women, Teenagers
  • Storage Instructions
  • Store In a Cool Palace
Product Description

WHAT ARE THE USES OF TRASTUZUMAB 440 MG INJECTION ?

Canmab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is mainly used to treat certain types of breast cancer or stomach cancer.

WHAT ARE THE POSSIBLE SIDE-EFFECTS OF CANMAB TRASTUZUMAB 440MG INJECTION ?

Some side effects may occur during the injection. Speak your doctor right away if you feel dizzy, nauseated, light-headed, weak, short of breath, or if you have a headache, fever, chills, sudden chest pain, wheezing, dry cough, hives, or swelling of your face, lips, tongue, or throat.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects.

 

Trade Information
  • Payment Terms
  • Western Union, Telegraphic Transfer (T/T), Letter of Credit at Sight (Sight L/C), Cheque, Cash in Advance (CID), Cash Advance (CA)
  • Supply Ability
  • 100 Per Week
  • Delivery Time
  • 1 Week
  • Main Export Market(s)
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia
  • Main Domestic Market
  • All India

3S CORPORATION
X


Back to top
3S CORPORATION All Rights Reserved.(Terms of Use)
Developed and Managed by Infocom Network Ltd.